Showing 65,261 - 65,280 results of 70,115 for search '(( 50 ((a decrease) OR (nn decrease)) ) OR ( a ((mean decrease) OR (point decrease)) ))', query time: 1.31s Refine Results
  1. 65261

    Table6_Acute changes in free and extracellular vesicle-associated circulating miRNAs and myokine profile in professional sky-runners during the Gran Sasso d’Italia vertical run.XLS... by M. Faraldi (13432389)

    Published 2022
    “…Nanoparticle tracking analysis revealed a similar EV size distribution in pre- and post-competition samples and a decreased concentration in post-competition samples related to pre-competition samples. …”
  2. 65262

    Table5_Acute changes in free and extracellular vesicle-associated circulating miRNAs and myokine profile in professional sky-runners during the Gran Sasso d’Italia vertical run.XLS... by M. Faraldi (13432389)

    Published 2022
    “…Nanoparticle tracking analysis revealed a similar EV size distribution in pre- and post-competition samples and a decreased concentration in post-competition samples related to pre-competition samples. …”
  3. 65263

    Expression pattern of IVSPER genes in <i>Hyposoter didymator</i> calyx cells during pupal developmental stages. by Ange Lorenzi (8124704)

    Published 2019
    “…<p>(A) Mean reads per kilo base per million mapped reads (RPKM) values are given from RNA-seq analyses (transformed by log10). …”
  4. 65264

    Table10_Acute changes in free and extracellular vesicle-associated circulating miRNAs and myokine profile in professional sky-runners during the Gran Sasso d’Italia vertical run.XL... by M. Faraldi (13432389)

    Published 2022
    “…Nanoparticle tracking analysis revealed a similar EV size distribution in pre- and post-competition samples and a decreased concentration in post-competition samples related to pre-competition samples. …”
  5. 65265

    Table9_Acute changes in free and extracellular vesicle-associated circulating miRNAs and myokine profile in professional sky-runners during the Gran Sasso d’Italia vertical run.XLS... by M. Faraldi (13432389)

    Published 2022
    “…Nanoparticle tracking analysis revealed a similar EV size distribution in pre- and post-competition samples and a decreased concentration in post-competition samples related to pre-competition samples. …”
  6. 65266

    Data_Sheet_1_Association Between Drinking Water Sources and Osteoarthritis Incidence in Chinese Elderly Population: National Population-Based Cohort Study.docx by Yangchang Zhang (7526468)

    Published 2022
    “…</p>Conclusion<p>Drinking tap water was associated with a low risk of OA among older adults in China. The use of clean water sources as a marker of decreased OA and arthritis risks must be revisited in low- and middle-income countries.…”
  7. 65267

    Table3_Acute changes in free and extracellular vesicle-associated circulating miRNAs and myokine profile in professional sky-runners during the Gran Sasso d’Italia vertical run.doc... by M. Faraldi (13432389)

    Published 2022
    “…Nanoparticle tracking analysis revealed a similar EV size distribution in pre- and post-competition samples and a decreased concentration in post-competition samples related to pre-competition samples. …”
  8. 65268

    MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2-7 by Hong Yin (20329)

    Published 2011
    “…GST and input CBP 1680–1892 have the same meanings as described in A above. MT2 1–235, MT2 1–311, and MT2 523–759, peptides of the MOZ partner from amino acids 1–235, 1–311, and 523–759 respectively were used in the incubation with the CH3 domain of CBP. . …”
  9. 65269

    Na<sub>v</sub>1.7 controls action potential threshold and contributes to the rising phase. by Aristos J. Alexandrou (2601481)

    Published 2016
    “…<p>A. Example current clamp voltage traces in which PF-05198007 application resulted in action potential block. …”
  10. 65270
  11. 65271

    Data Sheet 7_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
  12. 65272

    Fig 1 - by Hiroko Nemoto (14227637)

    Published 2022
    “…<p><b>1A and 1B. Western blotting analysis comparing doxorubicin (DOX) samples with control (CTRL) samples.…”
  13. 65273

    Image_2_Modest Gains After an 8-Week Exercise Program Correlate With Reductions in Non-traditional Markers of Cardiovascular Risk.pdf by Grace Liang (4398046)

    Published 2021
    “…</p><p>Conclusion: Modest improvements in physical fitness, physical activity, and/or weight loss through a short-term exercise program was associated with decreased plasma levels of plasminogen activator inhibitor, platelet derived growth factor beta, and angiopoietin, which have been associated with impaired fibrinolysis and inflammation.…”
  14. 65274

    Data Sheet 8_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
  15. 65275

    Table1_Association between serum albumin creatinine ratio and all-cause mortality in intensive care unit patients with heart failure.docx by Jiuyi Wang (18969451)

    Published 2024
    “…Multivariate adjusted Cox regression and subgroup analysis demonstrated that individuals in Q2 [hazard ratio (HR) 0.82, 95%CI 0.71∼0.96], Q3 (HR 0.76, 95%CI 0.64∼0.91) and Q4 (HR 0.62, 95%CI 0.50∼0.76) had a decreased risk of mortality compared to individuals in Q1 (lower levels of sACR) (p for trend < 0.001), and this inverse relationship was consistently observed across various subgroups. …”
  16. 65276

    Image2_Modification of Fibronectin by Non-Enzymatic Glycation Impairs K+ Channel Function in Rat Cerebral Artery Smooth Muscle Cells.JPEG by Yan Yang (33204)

    Published 2022
    “…Bovine FN (1 mg/ml) was glycated (gFN) for 5 days using methylglyoxal (50 mM), and albumin was similarly glycated as a non-matrix protein control. …”
  17. 65277

    Data Sheet 4_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
  18. 65278

    Clinical outcomes (MACE). by Tomohiko Shindo (612852)

    Published 2023
    “…The average weekly nitroglycerin use (times/week) was decreased from 5.50 to 2.44 in the LIPUS group and from 5.94 to 2.83 in the placebo group. …”
  19. 65279

    Baseline patient characteristics. by Tomohiko Shindo (612852)

    Published 2023
    “…The average weekly nitroglycerin use (times/week) was decreased from 5.50 to 2.44 in the LIPUS group and from 5.94 to 2.83 in the placebo group. …”
  20. 65280

    Data Sheet 9_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”